Shanghai's CARsgen Raises $30 Million for CAR-T Program

CARsgen Therapeutics, a Shanghai company developing CAR-T immunotherapies for solid tumors, completed a $30 million Series B round. CARsgen is currently conducting Phase I trials of two CAR-T immunotherapies: one for brain cancer and the other for liver cancer. The company's latest round was led by KTB Ventures, a Korean venture fund, and Jolly Innovation Ventures, which is backed by China's Jolly Pharma. Kaitai Capital and JIC Genesis Fountain Healthcare Ventures participated. More details.... Share this with colleagues: // //